Your browser is no longer supported. Please, upgrade your browser.
Settings
XLRN Acceleron Pharma Inc. daily Stock Chart
XLRN [NASD]
Acceleron Pharma Inc.
Index- P/E- EPS (ttm)-2.60 Insider Own0.50% Shs Outstand53.36M Perf Week-5.91%
Market Cap5.32B Forward P/E- EPS next Y-2.66 Insider Trans-24.71% Shs Float46.51M Perf Month-1.09%
Income-137.70M PEG- EPS next Q-0.53 Inst Own90.10% Short Float8.43% Perf Quarter11.60%
Sales75.60M P/S70.43 EPS this Y8.10% Inst Trans0.28% Short Ratio7.32 Perf Half Y125.68%
Book/sh7.76 P/B12.68 EPS next Y8.80% ROA-27.00% Target Price110.27 Perf Year134.00%
Cash/sh7.66 P/C12.85 EPS next 5Y- ROE-30.10% 52W Range37.01 - 108.50 Perf YTD85.63%
Dividend- P/FCF- EPS past 5Y-7.90% ROI-30.30% 52W High-9.29% Beta0.76
Dividend %- Quick Ratio15.10 Sales past 5Y38.30% Gross Margin- 52W Low165.93% ATR5.33
Employees237 Current Ratio15.10 Sales Q/Q53.60% Oper. Margin- RSI (14)51.76 Volatility4.90% 5.46%
OptionableYes Debt/Eq0.00 EPS Q/Q-28.30% Profit Margin- Rel Volume0.77 Prev Close98.42
ShortableYes LT Debt/Eq0.00 EarningsMay 11 AMC Payout- Avg Volume536.31K Price98.42
Recom2.00 SMA20-0.47% SMA507.46% SMA20051.78% Volume0 Change0.00%
Apr-06-20Downgrade Goldman Neutral → Sell $73
Feb-27-20Initiated Barclays Overweight $107
Feb-03-20Upgrade Morgan Stanley Equal-Weight → Overweight $122
May-29-19Resumed Goldman Neutral
May-24-19Resumed Citigroup Buy $66
May-03-19Downgrade Barclays Overweight → Equal Weight $54 → $45
Apr-22-19Resumed Oppenheimer Outperform
Feb-28-19Reiterated H.C. Wainwright Buy $72 → $67
Sep-10-18Resumed Morgan Stanley Equal-Weight $55
Jul-13-18Downgrade Morgan Stanley Overweight → Equal-Weight
Jul-10-18Downgrade Piper Jaffray Overweight → Neutral
Jun-29-18Upgrade Goldman Sell → Neutral
Feb-28-18Reiterated Barclays Overweight $50 → $54
Feb-26-18Upgrade JP Morgan Neutral → Overweight
Jan-18-18Resumed Credit Suisse Outperform $55
Nov-07-17Reiterated H.C. Wainwright Buy $57 → $62
Oct-12-17Initiated H.C. Wainwright Buy $57
Sep-15-17Initiated RBC Capital Mkts Sector Perform $44
Jun-13-17Downgrade Oppenheimer Outperform → Perform
May-17-17Initiated Goldman Sell $20
May-20-20 07:00AM  Acceleron Announces Presentations on REBLOZYL® (luspatercept-aamt) at the 2020 American Society of Clinical Oncology and European Hematology Association Virtual Annual Meetings Business Wire
May-19-20 07:00AM  Acceleron Announces Oral Presentation of PULSAR Phase 2 Trial Results in Virtual American Thoracic Society 2020 Conference Session on June 24, 2020 Business Wire
May-13-20 04:01PM  Acceleron Announces Publication in Science Translational Medicine Describing the Underlying Biology Behind Sotatercepts Potential as a Novel Therapy in Pulmonary Arterial Hypertension Business Wire
May-12-20 06:19PM  Edited Transcript of XLRN earnings conference call or presentation 11-May-20 9:00pm GMT Thomson Reuters StreetEvents
04:31PM  Acceleron Pharma Inc (XLRN) Q1 2020 Earnings Call Transcript Motley Fool
10:15AM  Acceleron (XLRN) Q1 Loss Wider Than Expected, Revenues Miss Zacks
May-11-20 05:45PM  Acceleron Pharma (XLRN) Reports Q1 Loss, Lags Revenue Estimates Zacks
04:05PM  Acceleron Reports First Quarter 2020 Operating and Financial Results Business Wire
May-05-20 07:00AM  Acceleron to Webcast First Quarter 2020 Operating and Financial Results on May 11, 2020 Business Wire
May-04-20 07:00AM  Acceleron Receives Priority Medicines (PRIME) Designation from European Medicines Agency (EMA) for Sotatercept in Pulmonary Arterial Hypertension Business Wire +9.33%
May-02-20 04:32PM  A strategy of buying the fastest-growing businesses in America has paid off for this investor in 2020 MarketWatch
Apr-30-20 04:16PM  Reblozyl (luspatercept) Receives Positive CHMP Opinion for the Treatment of Adults with Anemia in Beta Thalassemia and Myelodysplastic Syndromes Business Wire
Apr-24-20 11:41AM  7 Beautiful Biotech Stocks to Buy Here InvestorPlace +5.32%
Apr-21-20 05:31PM  Keros Therapeutics Shares Climb 70% After First Post-Covid-19 Biotech IPO GuruFocus.com -5.75%
Apr-15-20 02:35PM  Edited Transcript of XLRN earnings conference call or presentation 27-Feb-20 10:00pm GMT Thomson Reuters StreetEvents
Apr-09-20 02:24PM  An Intrinsic Calculation For Acceleron Pharma Inc. (NASDAQ:XLRN) Suggests It's 40% Undervalued Simply Wall St.
Apr-08-20 02:38PM  Biotech raises $96M IPO during downturn American City Business Journals
07:53AM  The Daily Biotech Pulse: Genmark Pre-Announces Q1 Outperformance, Sage to Eliminate 53% of Workforce, Keros IPO Benzinga
07:05AM  Acceleron Receives FDA Breakthrough Therapy Designation for Sotatercept in Pulmonary Arterial Hypertension Business Wire
Apr-07-20 04:05PM  Acceleron Announces Retirement of Director Jean George Business Wire
Apr-06-20 10:03PM  Bristol Myers/Acceleron's Reblozyl Label Expansion Gets FDA Nod Zacks +7.96%
04:53AM  Acceleron Receives Thumbs Up From Street On FDA Reblozyl Label Expansion SmarterAnalyst
Apr-03-20 05:08PM  U.S. Food and Drug Administration (FDA) Approves Reblozyl® (luspatercept-aamt), the First and Only Erythroid Maturation Agent, to Treat Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS) Business Wire
Mar-29-20 07:38PM  Do Hedge Funds Love Acceleron Pharma Inc (XLRN)? Insider Monkey
12:10PM  The Week Ahead In Biotech: Clinical Readouts, COVID-19 News Flow In Focus Amid Continuing Uncertainty Benzinga
Mar-26-20 06:59AM  New England Journal of Medicine Publishes Results from Pivotal Phase 3 BELIEVE Trial of Reblozyl (luspatercept-aamt) in Adult Patients With Beta Thalassemia Business Wire
Mar-09-20 04:05PM  Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Charcot-Marie-Tooth Disease Business Wire -6.61%
Mar-04-20 08:15AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Acceleron Pharma Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors ACCESSWIRE
Feb-27-20 05:35PM  Acceleron Pharma (XLRN) Reports Q4 Loss, Tops Revenue Estimates Zacks
Feb-26-20 08:49AM  Is a Surprise Coming for Acceleron Pharma (XLRN) This Earnings Season? Zacks
07:00AM  Acceleron to Participate in Two Upcoming Healthcare Investor Conferences Business Wire
Feb-20-20 04:10PM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Acceleron Pharma Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire
12:31PM  Acceleron Pharma (XLRN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Feb-19-20 07:59AM  Blood disorder startup files for $86M IPO American City Business Journals
Feb-18-20 10:46AM  Is Acceleron Pharma Inc.'s (NASDAQ:XLRN) CEO Pay Justified? Simply Wall St.
07:00AM  Acceleron to Webcast Fourth Quarter and Full Year 2019 Operating and Financial Results on February 27, 2020 Business Wire
Feb-03-20 10:18AM  Factors Setting the Tone for Bristol-Myers (BMY) Q4 Earnings Zacks
Jan-29-20 09:59AM  Biotech Stock Roundup: EPZM Drug Gets FDA Nod, XLRN & HEPA Surge on Study Data Zacks
08:30AM  The Daily Biotech Pulse: Novartis Earnings, Hepion's NASH Candidate Beats Rival Drugs, Annovis Bio To Debut Benzinga
Jan-28-20 04:22PM  Acceleron (XLRN) Up on Success of PAH Drug in Phase II Study Zacks +50.16%
01:48PM  5 'Strong Buy' Biotech Stocks With Rapidly Approaching Catalysts Kiplinger
10:20AM  Acceleron Stock Is Skyrocketing After Surprise Success for Heart Drug Barrons.com
08:13AM  Dow Jones Futures Rebound After China Coronavirus Slams Stock Market Rally; Apple, AMD On Tap Investor's Business Daily
07:12AM  The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics Benzinga
05:26AM  Acceleron stock soars on lung drug trial data American City Business Journals
Jan-27-20 06:06PM  Acceleron Stock Set To Soar At Open To Record High Here's Why Investor's Business Daily
04:22PM  Acceleron Pharma stock soars more than 50% on hypertension drug study MarketWatch
04:01PM  Acceleron Announces Sotatercept Achieved Primary and Secondary Endpoints in the PULSAR Phase 2 Placebo-Controlled Trial in Patients with Pulmonary Arterial Hypertension Business Wire
12:37PM  Acceleron Soars in After-Hours Trading on Positive Trial Results for Hypertension Treatment TheStreet.com
Jan-23-20 04:15PM  Acceleron Announces Change to Executive Management Team Business Wire
Jan-13-20 06:13PM  2019 Review: Top Hedge Fund Stocks vs. Acceleron Pharma Inc (XLRN) Insider Monkey
Jan-09-20 06:59AM  New England Journal of Medicine Publishes Results of Pivotal Phase 3 Reblozyl® (luspatercept-aamt) MEDALIST Trial Business Wire
Jan-06-20 07:00AM  Acceleron to Participate in the 38th Annual J.P. Morgan Healthcare Conference Business Wire
Jan-01-20 02:31PM  The Acceleron Pharma (NASDAQ:XLRN) Share Price Has Gained 93% And Shareholders Are Hoping For More Simply Wall St.
Dec-31-19 11:01AM  Acceleron, Fulcrum Therapeutics Ink Deal for Pulmonary Disease Zacks
Dec-30-19 07:30AM  Acceleron and Fulcrum Therapeutics Announce Pulmonary Research and Discovery Collaboration Agreement Business Wire
Dec-17-19 10:08AM  Agios' Tibsovo Wins FDA's Breakthrough Therapy Tag for MDS Zacks
Dec-09-19 04:30PM  Reblozyl® (luspatercept-aamt) Studies Evaluating Treatment of Anemia in Rare Blood Diseases Presented at American Society of Hematology (ASH) Annual Meeting Business Wire
09:22AM  Bristol-Myers' (BMY) Lymphoma Drug Meets Goals in Key Study Zacks
07:30AM  Acceleron Appoints Jay T. Backstrom, M.D., M.P.H., to Newly Created Role as Head of Research and Development Business Wire
Dec-06-19 04:07PM  Hedge Funds Are Buying Acceleron Pharma Inc (XLRN) Insider Monkey
12:05PM  Bristol-Myers Squibb and Acceleron Pharma Provide Update on FDA Advisory Committee for Reblozyl® (luspatercept-aamt) Business Wire
08:00AM  Acceleron Appoints Global Innovation and Drug Development Executive Kemal Malik, MB BS, to its Board of Directors Business Wire
Dec-04-19 04:01PM  Acceleron Named a "Most Honored" Company in Institutional Investor 2020 "All-America Executive Team" Rankings Business Wire
10:08AM  Bristol-Myers' Reblozyl to be Reviewed by FDA Committee Zacks
Dec-03-19 11:07AM  Stock Upgrades: Acceleron Pharma Shows Rising Relative Strength Investor's Business Daily
07:38AM  Bristol-Myers Squibb and Acceleron Pharma Announce FDA Advisory Committee Will Review Reblozyl® (luspatercept-aamt) for Use in Patients With Myelodysplastic Syndromes Business Wire
Dec-02-19 07:00AM  Acceleron to Host Conference Call and Webcast to Review Data Presented at the 61st American Society of Hematology Annual Meeting Business Wire
Nov-29-19 09:24AM  Geron (GERN) Stock Surges 40% YTD: What's Driving the Rally? Zacks
Nov-21-19 03:34PM  8 Stocks Ron Baron Continues to Buy GuruFocus.com
Nov-19-19 10:46AM  CRISPR Therapeutics stock jumps on early gene editing data American City Business Journals
Nov-13-19 03:43PM  Biotech Stock Roundup: SLDB Plunges, CELG Gets FDA Nod for Reblozyl & Other Updates Zacks
Nov-12-19 05:41AM  Edited Transcript of XLRN earnings conference call or presentation 6-Nov-19 3:00pm GMT Thomson Reuters StreetEvents
Nov-11-19 09:05AM  Celgene & Acceleron Get FDA Nod for Rare Blood Disorder Drug Zacks
Nov-08-19 04:25PM  How Celgene Added A New Drug To Its Wheelhouse A Month Early Investor's Business Daily +6.57%
02:24PM  Celgene's rare disease drug gets FDA approval MarketWatch
02:20PM  FDA approves Acceleron's blood disorder drug ahead of schedule American City Business Journals
12:33PM  FDA Approves REBLOZYL® (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular Red Blood Cell Transfusions Business Wire
Nov-06-19 09:05AM  Acceleron Pharma (XLRN) Reports Q3 Loss, Tops Revenue Estimates Zacks -15.43%
09:05AM  Acceleron Announces Luspatercept Presentations at the 61st American Society of Hematology Annual Meeting Business Wire
07:53AM  Acceleron Reports Third Quarter 2019 Operating and Financial Results Business Wire
Oct-30-19 10:33AM  Analysts Estimate Acceleron Pharma (XLRN) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-29-19 07:00AM  Acceleron to Webcast Third Quarter 2019 Operating and Financial Results on November 6, 2019 Business Wire
Oct-27-19 01:57PM  Is Acceleron Pharma Inc (XLRN) Going to Burn These Hedge Funds? Insider Monkey
Oct-11-19 09:45AM  Geron Starts Enrollment in Phase III MDS Study on Imetelstat Zacks
Oct-10-19 03:16PM  One Thing To Remember About The Acceleron Pharma Inc. (NASDAQ:XLRN) Share Price Simply Wall St.
Oct-01-19 10:36AM  Geron's Imetelstat Gets Fast Track Status for Myelofibrosis Zacks
Sep-18-19 10:33AM  Biotech Stock Roundup: BIIB Halts AD Study, AMGN Posts Positive MM Drug Data & More Zacks
10:33AM  Acceleron Discontinues Mid-Stage Muscular Dystrophy Study Zacks
Sep-17-19 04:38PM  This Biotech Just Flopped On A Test; Why Analysts Remain Bullish Investor's Business Daily
08:40AM  Acceleron Gives Up on Rare Genetic Disease. Analysts Are Still Bullish on the Stock. Barrons.com
07:23AM  The Daily Biotech Pulse: Acceleron Shelves Muscular Dystrophy Drug Trial, Aclaris Aces Late-Stage Study Benzinga
Sep-16-19 05:17PM  Acceleron Pharma stock down 4% after company halts treatment trial MarketWatch
04:30PM  Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Facioscapulohumeral Muscular Dystrophy Business Wire
Sep-11-19 10:49AM  Biotech Stock Roundup: AMGN's Lung Cancer Candidate, ALXN's Deal With Eidos in Focus Zacks
Sep-10-19 06:00PM  FDA Grants Orphan Drug Status to Acceleron's PAH Candidate Zacks
Sep-09-19 11:15AM  Acceleron's Pulmonary Arterial Hypertension Asset Receives Orphan Drug Designation Benzinga
07:00AM  Acceleron Receives FDA Orphan Drug Designation for Sotatercept in Pulmonary Arterial Hypertension Business Wire
Sep-04-19 09:03PM  Edited Transcript of XLRN earnings conference call or presentation 5-Aug-19 9:00pm GMT Thomson Reuters StreetEvents
Aug-29-19 10:18AM  Geron (GERN) Stock Rises 40% in 2019 So Far: Here's Why Zacks
Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which completed Phase III clinical trials for the treatment of myelodysplastic syndromes, beta-thalassemia, and myelofibrosis; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia. The company is also developing and sotatercept for the treatment of patients with pulmonary hypertension. In addition, the company is developing ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with facioscapulohumeral dystrophy and Charcot-Marie-Tooth disease; and ACE-2494, which is in Phase I clinical trials for the treatment of systemic muscle disorders. It has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerApr 09Option Exercise41.2017,226709,71128,442Apr 10 05:29 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerApr 09Sale88.1917,2261,519,16111,216Apr 10 05:29 PM
Veness Adam MSVP, General Counsel and Sec.Apr 08Option Exercise27.976,000167,82027,161Apr 10 05:30 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerApr 08Option Exercise32.7436,7741,204,12947,990Apr 10 05:29 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerApr 08Sale85.5136,7743,144,61411,216Apr 10 05:29 PM
Veness Adam MSVP, General Counsel and Sec.Apr 08Sale85.586,000513,50921,161Apr 10 05:30 PM
Zakrzewski Joseph SDirectorJan 07Option Exercise3.8818,75072,75031,500Jan 09 04:36 PM
Dable Habib JCEO and PresidentJan 03Sale51.243,732191,23067,151Jan 03 09:37 PM
KANGO SUJAYSVP, Chief Commercial OfficerJan 03Sale51.3748024,6579,570Jan 03 09:48 PM
Veness Adam MVP, General Counsel and Sec.Jan 03Sale51.2387544,82614,792Jan 03 09:51 PM
Veness Adam MVP, General Counsel and Sec.Jan 02Sale52.8343422,92815,667Jan 03 09:51 PM
Quisel John DEVP, Chief Business OfficerJan 02Sale52.525,842306,80653,316Jan 03 09:45 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerJan 02Sale52.505,579292,9234,847Jan 03 09:41 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerDec 13Sale50.2811,853595,96910,426Dec 17 06:39 PM
Veness Adam MVP, General Counsel and Sec.Sep 10Sale45.2082437,24116,101Sep 10 08:25 PM
Kumar RavindraSVP & Chief Scientific OfficerSep 10Sale45.243,389153,31886,986Sep 10 08:24 PM
Quisel John DEVP, Chief Business OfficerSep 10Sale45.233,584162,10459,158Sep 10 08:23 PM
MCLAUGHLIN KEVIN FSVP, CFO and TreasurerSep 10Sale45.308,000362,40022,279Sep 10 08:22 PM
Dable Habib JCEO and PresidentSep 10Sale45.235,625254,41270,883Sep 10 08:21 PM
Veness Adam MVP, General Counsel and Sec.Aug 09Sale45.003,268147,06016,925Aug 12 04:18 PM
Veness Adam MVP, General Counsel and Sec.Jul 16Sale40.7153821,90220,193Jul 17 05:49 PM
Quisel John DEVP, Chief Business OfficerJul 09Option Exercise4.828,90842,90862,742Jul 11 04:26 PM
George JeanDirectorJun 28Sale41.1711,812486,3000Jun 28 07:25 PM
George JeanDirectorJun 26Option Exercise26.3537,500988,17541,250Jun 28 07:25 PM
George JeanDirectorJun 26Sale39.1625,6881,005,94215,562Jun 28 07:25 PM
Zakrzewski Joseph SDirectorJun 14Buy38.055,000190,25012,750Jun 17 06:08 PM